Suchergebnisse - "Podar, Klaus"

PubPharm (256)

1

Retraction : Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage

enthalten in: Journal of immunology (Baltimore, Md. : 1950) | 2024

von Tai, Y. | Teoh, G. | Lin, B. | +8

RetractionOf: J Immunol. 2000 Dec 1;165(11):6347-55. - PMID 11086072

2

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma

enthalten in: American journal of hematology | 2024

von Ludwig, H. | Melchardt, T. | Sormann, S. | +23

3

Correction : Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications

enthalten in: Breast cancer research : BCR | 2024

von Bashari, M. | Fan, F. | Vallet, S. | +11

ErratumFor: Breast Cancer Res. 2016 Feb 26;18(1):26. - PMID 26921175

4

Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications

enthalten in: Breast cancer research | 2024

von Bashari, M. | Fan, F. | Vallet, S. | +11

5

The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma

enthalten in: Expert opinion on drug discovery | 2024

von Strassl, I. | Podar, K.

6

Retraction : Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of β1-Integrin and Phosphatidylinositol 3'-Kinase/AKT Signaling

enthalten in: Cancer research | 2024

von Tai, Y. | Podar, K. | Catley, L. | +12

RetractionOf: Cancer Res. 2003 Sep 15;63(18):5850-8. - PMID 14522909

7

Retraction : Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications

enthalten in: Cancer research | 2024

von Tai, Y. | Catley, L. | Mitsiades, C. | +11

RetractionOf: Cancer Res. 2004 Apr 15;64(8):2846-52. - PMID 15087402

8

Targeting mtDAMPed macrophages for MM therapy

enthalten in: Blood | 2023

von Podar, K.

CommentOn: Blood. 2023 Jun 22;141(25):3065-3077. - PMID 36888932

9

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR)

enthalten in: Cancers | 2023

von Benda, M. | Ulmer, H. | Weger, R. | +12

10

Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM) : Therapeutic implications

enthalten in: Cytokine | 2023

von Aksoy, O. | Lind, J. | Sunder-Plaßmann, V. | +2

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[26]